Retatrutide

What TRIUMPH-1 showed (and why it matters)

TRIUMPH-1 ran roughly 2,200 adults over 80 weeks across multiple dose arms against placebo - the trial the FDA will lean on. Beyond the top-line 12 mg numbers above, two findings deserve their own callout:

• An extension cohort with the most severe obesity (BMI 35+) kept losing through week 104: up to 85 lbs / 30.3% body weight. Most weight-loss drugs plateau by week 60. This one kept going.
• 4 mg dose (the low dose) delivered 47.2 lbs / 19.0% at 80 weeks - with FEWER patients dropping out for side effects than the placebo group. That number is the quietly enormous finding of the readout. We'll come back to it.

Why this matters: tens of millions of adults live in the gap between "diet and exercise didn't work" and "I'm not getting a surgeon to staple my stomach," and that gap has had two real drugs in it - semaglutide and tirzepatide. Retatrutide raises the ceiling by another 6 to 8 percentage points of body weight. For someone 280 lbs, that's another 20+ lbs on top of what tirzepatide could do.

None of that makes it the right choice for everyone. If (and only if) the FDA approves it on the 2027 timeline, it joins the menu as the most effective of the three - but the right entry point for most people will still be tirzepatide, which is approved, available, and already produces excellent results. Retatrutide becomes the option for people who plateau on tirzepatide, or whose starting weight is high enough that they need every percentage point.

The low-dose story (this is the actual news)

The 28.3% headline will dominate coverage, and it deserves the attention. But the part of the readout that matters most for actual patients is buried lower in the data: the 4 mg dose.

4 mg is the first step above the starter dose. Most weight-loss drugs make you climb a long titration ladder (a slow dose-ramp to let your gut adjust); for retatrutide the ladder ran 2 mg starter, then 4 mg, 8 mg, and 12 mg, about a month per step. The high doses, where the headline numbers come from, are also where the gut side effects live: nausea, vomiting, weeks where food doesn't sound good.

At 4 mg - one step from the starter - patients lost 47.2 lbs on average (19.0% of body weight) over 80 weeks, competitive with tirzepatide's headline number from SURMOUNT-1 (22.5% at 72 weeks on the top dose). But here is the unusual finding: side-effect discontinuations were LOWER on the 4 mg arm than on placebo. Lower than placebo. The people taking the drug tolerated it better than the people taking nothing.

This matters because the real-world story of GLP-1s is that a meaningful slice of patients climb the dose ladder, hit nausea they can't live with, and quit - not because the drug failed, but because the high-dose side effects were brutal. Get 19% weight loss at a dose most people don't need to climb past, with no side-effect discontinuation premium, and the drug becomes useful for a far wider population - the low dose changes who can actually stay on it long enough to get results.

So when retatrutide hits pharmacies, the smart conversation with a prescriber may not be "give me the 12 mg dose and the 70-lb number" but "let me sit at 4 mg, get the 19% result, and see how I feel before I climb." The 4 mg story is the consumer story. The 12 mg story is the press release.

What people use it for

An S-tier triple agonist still in Phase 3 trials. Where it is aimed:

• Weight loss The headline result from the TRIUMPH-1 trial
• Type 2 diabetes A parallel trial indication
• Fatty liver A strong signal in early data

See the full Retatrutide dosing protocol ->

Status

TRIUMPH-1 isn't the only anchor trial. The earlier pivotal TRIUMPH-4 (obesity with knee osteoarthritis, December 2025) had already cleared the bar on both weight loss and knee pain (figures below), so Lilly now has the two obesity trials it needs to file. The NDA is the next milestone, with a likely FDA decision in 2027 - closer than ever, but still 12 to 18 months out, not weeks.

Side effects looked like the rest of the GLP-1 class plus two retatrutide-specific signals. First, dysesthesia - abnormal skin sensitivity, like low-grade pins-and-needles - in roughly 1 in 5 patients on the 12 mg dose, almost always mild and rarely a reason to stop. Second, resting heart rate ticked up a few beats per minute at the high dose, peaking mid-trial and partially settling after. No spike in heart attacks or major cardiovascular events. Side-effect discontinuations ran higher than placebo on the 12 mg arm (as a high-dose triple-agonist would predict), lower than placebo on the 4 mg arm.

The series isn't done. More Phase 3 readouts are queued in 2026, including the type-2-diabetes-with-obesity trial (TRIUMPH-2), each adding to the eventual label - cardiovascular outcomes, sleep apnea, fatty liver, kidney function. The full picture is still filling in.

Retatrutide and your heart rate

This is real, and it's worth understanding before the hype cycle muddies it. In the Phase 2 obesity trial (Jastreboff et al., NEJM 2023), resting heart rate rose an average of roughly 6 to 7 beats per minute on the top 12 mg dose. It was dose-dependent, peaked around week 24, then drifted back toward baseline by weeks 36 to 48. A faster resting pulse is a monitored class effect of GLP-based drugs; retatrutide's runs a bit higher than semaglutide or tirzepatide because of its glucagon arm, the same third lever that drives the bigger weight loss. There was no rise in heart attacks or major cardiac events in the trials. Heart rate variability data is thin and not yet conclusive.

What to do about it is the part people get wrong. The fix for a fast or pounding heart rate is not something you self-prescribe. A persistent or symptomatic fast heart rate warrants a clinical evaluation - rate control, if any, is your physician's call, not a thing you buy off a forum. The influencer move of rotating off retatrutide, switching to tirzepatide, or adding a beta-blocker to mask the bump is an unproven n=1 protocol with zero outcome data; it gets discussed in the community, but treat it as a question for a doctor, not a recommendation. Level of evidence: the heart-rate signal itself is RCT-grade and well documented. Everything beyond "see your physician" is not. Retatrutide is also still investigational and not FDA-approved.

Legal status

Retatrutide is not FDA-approved, and not approved in any country as of May 2026. A positive TRIUMPH-1 doesn't change that - approval is a separate process that follows the readout. It's still an investigational drug, available only inside clinical trials, not through normal prescribing channels.

In practice: the services prescribing tirzepatide and semaglutide can't legally carry it, and compounding pharmacies generally can't either - this is a novel patented molecule, not a peptide that fell out of the patent system, so Lilly hasn't licensed compounding production. Anything sold as "retatrutide" by research peptide vendors is almost certainly not the trial-grade molecule, with no way to verify what's in the bottle. The right move is to wait: tirzepatide and semaglutide have years of approved-drug safety records, where retatrutide has only trial data - not the same thing as a real-world track record.

The cost and access fight that's coming

Retatrutide is a novel, fully-patented molecule, so Lilly can charge whatever the market will bear - and they will. Based on how they priced Zepbound and Mounjaro, expect launch pricing of $1,000 to $1,500 a month without insurance. That's the cash price; the fight will be over coverage.

BMI of 30+ or type 2 diabetes, and insurance MIGHT cover it on day one - same logic that gets people approved for Zepbound. BMI between 27 and 30, or want it preventively, and it's probably a no for the first year, until the cardiovascular and metabolic outcomes data lands. Optimizing body composition without a qualifying diagnosis is a hard no - you're paying cash, and at $1,200 a month over the typical year-and-a-half arc that's $20,000+ out of pocket: for most working adults, not "is this worth it" math but "is this even on the table" math.

The bottleneck isn't the science - it's whoever pays the bill. That's also why the lower 4 mg dose matters here: it costs less, requires less drug, and is more likely to win insurance approval than the 12 mg headline number.

Where to source

There's no legitimate path until commercial launch (see legal status above); the move in the meantime is tirzepatide - available, proven, 22%+ weight loss in trials. Subscribe below and we'll cover approval timelines, launch pricing, and the insurance fight in the weekly dispatch as they happen.

Three studies worth reading

Watch: Huberman on peptides (June 2026)

Retatrutide comes up in the June 2026 episode with one blunt, practical warning: there is no reliable third-party testing for gray-market peptides, so for genuinely pure retatrutide you currently have to go through the manufacturer. The single most important sourcing line for this molecule.

Source: Huberman Lab - Peptides: The Science, Uses & Safety (Dr. Abud Bakri). See our full decode of what he says about every peptide.

Subscribe to the dispatch